<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="cited. Abstract Aim To assess the effect of treating chronic" exact="hepatitis" post="C virus (HCV) infection with direct acting antiviral drugs"/>
 <result pre="antiviral drugs (DAAs) on glycemic control in patients with concomitant" exact="diabetes mellitus" post="(DM). Methods We performed a retrospective case-control study in"/>
 <result pre="(DM). Methods We performed a retrospective case-control study in a" exact="viral hepatitis" post="ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014"/>
 <result pre="Methods We performed a retrospective case-control study in a viral" exact="hepatitis" post="ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014"/>
 <result pre="clinic patient ages 18 years and above with treatment-naïve/biopsy-proven chronic" exact="hepatitis" post="C and DM (hemoglobin A1C level ≥ 6.5%) who were eligible"/>
 <result pre="group of 59 patients did not receive treatment for their" exact="hepatitis" post="C and was followed in the clinic. Patients in"/>
 <result pre="receive treatment either due to insurance issues or refusal of" exact="hepatitis" post="C treatment. Results Fifty-five of the 59 patients treated"/>
 <result pre="0.2%). Conclusion This controlled study demonstrated that treatment of chronic" exact="hepatitis" post="C with DAAs results in statistically significant and meaningful"/>
 <result pre="1. Introduction Diabetes mellitus (DM) is strongly associated with chronic" exact="hepatitis" post="C virus (HCV) infection. It has been estimated that"/>
 <result pre="cohort of HCV patients with overt DM seen at a" exact="viral hepatitis" post="clinic in Shreveport, Louisiana. An untreated group of patients"/>
 <result pre="of HCV patients with overt DM seen at a viral" exact="hepatitis" post="clinic in Shreveport, Louisiana. An untreated group of patients"/>
 <result pre="in Shreveport, Louisiana. An untreated group of patients with chronic" exact="hepatitis" post="C was included as controls. 2. Methods 2.1. Study"/>
 <result pre="adult patients (age ≥ 18 years) with treatment-naïve, biopsy-proven chronic" exact="hepatitis" post="C and concomitant DM (hemoglobin A1C (HbA1C) level ≥ 6.5% [12]) seen"/>
 <result pre="and concomitant DM (hemoglobin A1C (HbA1C) level ≥ 6.5% [12]) seen in a" exact="viral hepatitis" post="clinic in Shreveport, Louisiana, clinic between November 1, 2014,"/>
 <result pre="concomitant DM (hemoglobin A1C (HbA1C) level ≥ 6.5% [12]) seen in a viral" exact="hepatitis" post="clinic in Shreveport, Louisiana, clinic between November 1, 2014,"/>
 <result pre="eligible for inclusion in the study. Clinic patients with chronic" exact="hepatitis" post="C and with DM were identified by ICD-10-CM codes"/>
 <result pre="with DAAs and 59 controls who were not treated for" exact="hepatitis" post="C (because of insurance or refusal of hepatitis C"/>
 <result pre="treated for hepatitis C (because of insurance or refusal of" exact="hepatitis" post="C treatment) and were followed in the clinic. Clinic"/>
 <result pre="were excluded from the study. All patients were screened for" exact="hepatocellular carcinoma" post="(HCC), and none were found to have HCC. We"/>
 <result pre="RNA was checked at 4, 8, and 12 weeks during" exact="hepatitis" post="C treatment and at 6 months after completion of"/>
 <result pre="whereas in the 25 patients with either severe fibrosis or" exact="cirrhosis" post="at baseline (F3-F4), mean HbA1C decreased 0.9 ± 0.3%"/>
 <result pre="is (are) unclear. Matsui et al. demonstrated in vitro that" exact="hepatitis" post="C viral replication suppresses GLUT2 expression and hence cellular"/>
 <result pre="[16]. Conversely, there has been speculation that insulin resistance and" exact="hyperglycemia" post="promote hepatitis C viral replication and are associated with"/>
 <result pre="there has been speculation that insulin resistance and hyperglycemia promote" exact="hepatitis" post="C viral replication and are associated with worse clinical"/>
 <result pre="achieved with interferon alpha plus ribavirin in patients with chronic" exact="hepatitis" post="C could improve glycemic control and insulin sensitivity [19]"/>
 <result pre="effects of the medications used to achieve a SVR, including" exact="hemolytic anemia" post="from ribavirin which can falsely lower HbA1C levels and"/>
 <result pre="of the medications used to achieve a SVR, including hemolytic" exact="anemia" post="from ribavirin which can falsely lower HbA1C levels and"/>
 <result pre="direct acting antiviral drugs (DAAs) on the severity of coexisting" exact="diabetes mellitus" post="(DM) [2–6]. In the largest study, Hum et al."/>
 <result pre="was only seen in veterans without severe hepatic fibrosis or" exact="cirrhosis" post="[2]. In contrast, in our study with roughly equal"/>
 <result pre="on their reduced HbA1C levels. Because the patients with chronic" exact="hepatitis" post="C treated with DAAs in our study did not"/>
 <result pre="should be aware that glycemia will probably improve and that" exact="hypoglycemia" post="might occur, particularly if the patient is receiving insulin,"/>
 <result pre="blood glucose monitoring at home and in the clinic. However," exact="hypoglycemia" post="has not been commonly reported in HCV treatment studies"/>
 <result pre="manuscript. References 1GastaldiG.GoossensN.ClémentS.NegroF.Current level of evidence on causal association between" exact="hepatitis" post="C virus and type 2 diabetes: a reviewJournal of"/>
 <result pre="glycemic control of type 2 diabetes after successful treatment of" exact="hepatitis" post="C virusDiabetes Care20174091173118010.2337/dc17-048528659309 3Abdel AlemS.ElsharkawyA.FouadR.et al.Improvement of glycemic state"/>
 <result pre="2 diabetes following direct acting antiviral treatment of genotype 1" exact="hepatitis" post="CCase Reports in Hepatology20162016310.1155/2016/7807921 8DrazilovaS.JanickoM.SkladanyL.et al.Glucose metabolism changes in"/>
 <result pre="in Hepatology20162016310.1155/2016/7807921 8DrazilovaS.JanickoM.SkladanyL.et al.Glucose metabolism changes in patients with chronic" exact="hepatitis" post="C treated with direct acting antiviralsCanadian Journal of Gastroenterology"/>
 <result pre="glucose metabolism and reduction of pre-diabetes in patients with chronic" exact="hepatitis" post="CJournal of Gastrointestinal and Liver Diseases201827328128910.15403/jgld.2014.1121.273.daa30240472 10MoralesA. L.JungaZ.SinglaM. B.SjogrenM.TorresD.Hepatitis"/>
 <result pre="interobserver variations in liver biopsy interpretation in patients with chronic" exact="hepatitis" post="CHepatology199429p. 15 14BedossaP.PoynardT.An algorithm for the grading of activity"/>
 <result pre="15 14BedossaP.PoynardT.An algorithm for the grading of activity in chronic" exact="hepatitis" post="CHepatology199624228929310.1002/hep.5102402018690394 15ChungR. T.GhanyM. G.KimA. Y.et al.Hepatitis C guidance 2018"/>
 <result pre="guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating" exact="hepatitis" post="C virus infectionClinical Infectious Diseases201867101477149210.1093/cid/ciy58530215672 16MatsuiC.ShojiI.KanedaS.SianiparI. R.DengL.HottaH.Hepatitis C virus"/>
 <result pre="Virology20128623129031291110.1128/JVI.01418-1222993150 17NegroF.FortonD.CraxìA.SulkowskiM. S.FeldJ. J.MannsM. P.Extrahepatic morbidity and mortality of chronic" exact="hepatitis" post="CGastroenterology201514961345136010.1053/j.gastro.2015.08.03526319013 18NegroF.Facts and fictions of HCV and comorbidities: steatosis,"/>
 <result pre="hepatitis CGastroenterology201514961345136010.1053/j.gastro.2015.08.03526319013 18NegroF.Facts and fictions of HCV and comorbidities: steatosis," exact="diabetes mellitus," post="and cardiovascular diseasesJournal of Hepatology2014611 SupplS69S7810.1016/j.jhep.2014.08.00325443347 19TahraniA.BowlerL.SinghP.CoatesP.Resolution of diabetes"/>
 <result pre="type 2 diabetic patient treated with IFN-?? and ribavirin for" exact="hepatitis" post="CEuropean journal of gastroenterology &amp;amp; hepatology200618329129310.1097/00042737-200603000-0001116462544 20AraseY.SuzukiF.SuzukiY.et al.Sustained virological"/>
 <result pre="reduces incidence of onset of type 2 diabetes in chronic" exact="hepatitis" post="CHepatology200949373974410.1002/hep.2270319127513 21GrossB. N.CrossL. B.FoardJ. C.WoodY. A.Falsely low hemoglobin A1c"/>
 <result pre="levels in a patient receiving ribavirin and peginterferon alfa-2b for" exact="hepatitis" post="CPharmacotherapy200929112112310.1592/phco.29.1.12119113800 22GreenbergP. D.RosmanA. S.EldeiryL. S.NaqviZ.BräuN.Decline in haemoglobin A1c values"/>
 <result pre="values in diabetic patients receiving interferon-alpha and ribavirin for chronic" exact="hepatitis" post="CJournal of Viral Hepatitis200613961361710.1111/j.1365-2893.2006.00729.x16907848 23StineJ. G.WynterJ. A.NiccumB.KellyV.CaldwellS. H.ShahN. L.Effect"/>
 <result pre="with direct acting antiviral on glycemic control in patients with" exact="diabetes mellitus" post="and chronic hepatitis CAnnals of Hepatology201716221522010.5604/16652681.123158131153414 24ChaudhuryC. S.SheehanJ.ChairezC.et al.No"/>
 <result pre="on glycemic control in patients with diabetes mellitus and chronic" exact="hepatitis" post="CAnnals of Hepatology201716221522010.5604/16652681.123158131153414 24ChaudhuryC. S.SheehanJ.ChairezC.et al.No improvement in hemoglobin"/>
 <result pre="of Hepatology201716221522010.5604/16652681.123158131153414 24ChaudhuryC. S.SheehanJ.ChairezC.et al.No improvement in hemoglobin a1c following" exact="hepatitis" post="c viral clearance in patients with and without HIVThe"/>
 <result pre="Infectious Diseases20172171475010.1093/infdis/jix51729161418 25HuangJ.-F.HuangC.-F.YehM.-L.et al.The outcomes of glucose abnormalities in chronic" exact="hepatitis" post="C patients receiving interferon-free direct antiviral agentsThe Kaohsiung Journal"/>
 <result pre="glycaemic control in patients with type 2 diabetes and chronic" exact="hepatitis" post="CLiver International20193961027103210.1111/liv.1403130570808 27GiladA.FrickerZ. P.HsiehA.ThomasD. D.ZahorianT.NunesD. P.Sustained improvement in type"/>
 <result pre="CLiver International20193961027103210.1111/liv.1403130570808 27GiladA.FrickerZ. P.HsiehA.ThomasD. D.ZahorianT.NunesD. P.Sustained improvement in type 2" exact="diabetes mellitus" post="is common after treatment of hepatitis C virus with"/>
 <result pre="in type 2 diabetes mellitus is common after treatment of" exact="hepatitis" post="C virus with direct-acting antiviral therapyJournal of Clinical Gastroenterology201953861662010.1097/mcg.000000000000116830614943"/>
 <result pre="control by direct-acting antiviral agent treatment in egyptian type 2" exact="diabetes mellitus" post="patients with chronic hepatitis C genotype 4Diabetes &amp;amp; Metabolism"/>
 <result pre="treatment in egyptian type 2 diabetes mellitus patients with chronic" exact="hepatitis" post="C genotype 4Diabetes &amp;amp; Metabolism Journal201741431632110.4093/dmj.2017.41.4.31628868829 29MadaP. K.MalusM. E.ChenB.et"/>
 <result pre="sustained virologic response achieved through newer direct acting antivirals in" exact="hepatitis" post="C infection on diabetes mellitusOpen Forum Infectious Diseases20185suppl_1p. S65610.1093/ofid/ofy210.1875"/>
 <result pre="BMI (kg/m2)a 30.8 ± 0.8 29.1 ± 0.8 NS Cirrhosis/no" exact="cirrhosis" post="27/32 26/33 NS Viral load (copies × 106)a 3.8"/>
 <result pre="BMI: body mass index; HbA1C: hemoglobin A1C level (%); HCV:" exact="hepatitis" post="C virus; NS: P value not statistically significant (P"/>
 <result pre="regression model predicting final HbA1C levels in 118 patients with" exact="hepatitis" post="C and diabetes mellitus (n = 118). Covariate (1)"/>
 <result pre="final HbA1C levels in 118 patients with hepatitis C and" exact="diabetes mellitus" post="(n = 118). Covariate (1) Reference variable (0) Estimate"/>
 <result pre="0.460 0.497 Genotype 1 Non-1 -0.104 0.080 0.772 Moderate/severe chronic" exact="hepatitis" post="Minimal/mild chronic hepatitis 0.474 0.960 0.326 Baseline serum ALT"/>
 <result pre="1 Non-1 -0.104 0.080 0.772 Moderate/severe chronic hepatitis Minimal/mild chronic" exact="hepatitis" post="0.474 0.960 0.326 Baseline serum ALT level — -0.026"/>
 <result pre="0.131 Pretreatment HbA1C — 0.209 1.730 0.189 Severe fibrosis or" exact="cirrhosis" post="No, mild, or significant fibrosis 0.066 0.020 0.889 Treatment"/>
 <result pre="antiviral agents for HCV; HbA1C: hemoglobin A1C level (%); HCV:" exact="hepatitis" post="C virus; P: probability."/>
</results>
